Humanwell Healthcare (Group)Ltd Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Humanwell Healthcare (Group)Ltd wird ein jährliches Gewinn- und Umsatzwachstum von 13.7% bzw. 6.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.5% betragen.

Wichtige Informationen

13.7%

Wachstumsrate der Gewinne

13.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	19.0%
Wachstumsrate der Einnahmen	6.5%
Zukünftige Eigenkapitalrendite	11.5%
Analystenabdeckung	Low
Zuletzt aktualisiert	06 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Investors Still Aren't Entirely Convinced By Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Earnings Despite 42% Price Jump

Oct 21

Is Humanwell Healthcare (Group)Ltd (SHSE:600079) Using Too Much Debt?

Sep 17

There's No Escaping Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Muted Earnings Despite A 26% Share Price Rise

Aug 04

Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Low P/E No Reason For Excitement

May 22

Gewinn- und Umsatzwachstumsprognosen

SHSE:600079 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	29,739	2,757	N/A	3,298	3
12/31/2025	27,845	2,420	N/A	2,606	3
12/31/2024	26,451	2,219	N/A	1,707	2
9/30/2024	25,556	1,955	1,191	2,487	N/A
6/30/2024	25,003	1,922	809	2,428	N/A
3/31/2024	24,666	1,956	428	2,306	N/A
12/31/2023	24,525	2,134	9	1,967	N/A
9/30/2023	24,194	2,028	615	2,545	N/A
6/30/2023	24,142	2,305	761	2,495	N/A
3/31/2023	23,379	2,235	344	1,959	N/A
12/31/2022	22,338	2,484	-672	2,441	N/A
9/30/2022	21,943	2,448	-970	2,225	N/A
6/30/2022	21,459	2,158	-1,059	2,140	N/A
3/31/2022	21,063	1,931	-964	2,272	N/A
12/31/2021	20,549	1,317	476	2,179	N/A
9/30/2021	20,384	1,630	326	1,816	N/A
6/30/2021	20,694	1,276	852	2,259	N/A
3/31/2021	20,465	1,313	703	1,937	N/A
12/31/2020	20,680	1,006	992	2,090	N/A
9/30/2020	20,549	710	1,128	2,024	N/A
6/30/2020	20,940	898	1,018	1,721	N/A
3/31/2020	21,119	806	1,158	1,911	N/A
12/31/2019	21,807	843	1,228	2,038	N/A
9/30/2019	21,200	-2,261	958	1,958	N/A
6/30/2019	20,317	-2,523	238	1,473	N/A
3/31/2019	19,459	-2,362	-97	1,133	N/A
12/31/2018	18,634	-2,358	-714	603	N/A
9/30/2018	18,299	778	-1,711	-256	N/A
6/30/2018	17,422	2,195	N/A	-196	N/A
3/31/2018	16,554	2,049	N/A	-60	N/A
12/31/2017	15,446	2,069	N/A	93	N/A
9/30/2017	14,240	2,149	N/A	193	N/A
6/30/2017	13,478	781	N/A	170	N/A
3/31/2017	12,979	881	N/A	159	N/A
12/31/2016	12,331	832	N/A	526	N/A
9/30/2016	11,898	836	N/A	597	N/A
6/30/2016	11,294	781	N/A	498	N/A
3/31/2016	10,602	668	N/A	141	N/A
12/31/2015	10,054	654	N/A	311	N/A
9/30/2015	8,941	565	N/A	96	N/A
6/30/2015	8,213	523	N/A	191	N/A
3/31/2015	7,579	494	N/A	556	N/A
12/31/2014	7,052	452	N/A	503	N/A
9/30/2014	6,754	435	N/A	887	N/A
6/30/2014	6,518	440	N/A	901	N/A
3/31/2014	6,239	425	N/A	747	N/A
12/31/2013	6,010	418	N/A	498	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 600079Das prognostizierte Gewinnwachstum (13.7% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 600079Die Erträge des Unternehmens (13.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (26.2% pro Jahr).

Hohe Wachstumserträge: 600079Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 600079Die Einnahmen des Unternehmens (6.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (13.8% pro Jahr).

Hohe Wachstumseinnahmen: 600079Die Einnahmen des Unternehmens (6.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 600079Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.5%).

Humanwell Healthcare (Group)Ltd Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to CN¥33.31

Analysts update estimates

Price target lowered to CN¥10.32

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.27 in 3Q 2023)

Investors Still Aren't Entirely Convinced By Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Earnings Despite 42% Price Jump

Upcoming dividend of CN¥0.15 per share

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 21%

Is Humanwell Healthcare (Group)Ltd (SHSE:600079) Using Too Much Debt?

Investor sentiment deteriorates as stock falls 16%

There's No Escaping Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Muted Earnings Despite A 26% Share Price Rise

Second quarter 2024 earnings released: EPS: CN¥0.38 (vs CN¥0.41 in 2Q 2023)

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2024 Results on Aug 15, 2024

Dividend of CN¥0.46 announced

Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Low P/E No Reason For Excitement

First quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.41 in 1Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Investor sentiment improves as stock rises 17%

Humanwell Healthcare (Group) Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.35 in 2Q 2022)

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Novo Holdings A/S agreed to acquire The Ritedose Corporation from AGIC Capital, Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) and others.

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

Price target decreased to CN¥33.31

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 1Q 2020)

Investor sentiment improved over the past week

New 90-day low: CN¥25.74

Investor sentiment deteriorated over the past week

New 90-day low: CN¥27.26

New 90-day low: CN¥30.20

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥30.82

Analysts update estimates

Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) entered into a preliminary letter of intent to acquire an additional 13% stake in YiChang Humanwell Pharmaceutical Co., Ltd from Li Jie, Chen Xiaoqing, and Xu Huabin.

Price target lowered to CN¥10.32

New 90-day high - CN¥38.00

New 90-day high - CN¥36.85

Chongqing Pharmaceutical (Group) Co., Ltd. signed the Sichuan Humanwell Pharmaceutical Co., Ltd. Equity Transfer Contract to acquire 70% stake in Sichuan Humanwell Pharmaceutical Co., Ltd from Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) for approximately CNY 360 million.

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2020 Results on Aug 22, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken